

Marjolein de Bruin-Weller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2993454/publications.pdf>

Version: 2024-02-01

95
papers

6,205
citations

109137

35
h-index

74018

75
g-index

98
all docs

98
docs citations

98
times ranked

3871
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303.	6.3	884
2	Epidemiology of atopic dermatitis in adults: Results from an international survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1284-1293.	2.7	546
3	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. <i>British Journal of Dermatology</i> , 2018, 178, 1083-1101.	1.4	380
4	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 729-747.	1.3	329
5	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.4	288
6	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2021, 157, 1047.	2.0	236
7	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	1.3	220
8	Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2169-2181.	6.3	199
9	Biomarkers for atopic dermatitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 453-460.	1.1	185
10	Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1074-1084.	0.6	156
11	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	0.6	155
12	Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1778-1780.e1.	2.0	132
13	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 443-456.	3.3	130
14	Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 730-737.	1.5	127
15	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018, 178, 768-775.	1.4	127
16	Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 116-126.	2.7	105
17	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 476-485.	1.3	101
18	Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. <i>British Journal of Dermatology</i> , 2019, 180, 1248-1249.	1.4	97

#	ARTICLE	IF	CITATIONS
19	Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology. <i>Journal of Medical Internet Research</i> , 2017, 19, e300.	2.1	91
20	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1644-1659.	1.3	85
21	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 567-577.	3.3	78
22	Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 275-281.	0.6	77
23	Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. <i>Journal of Neurology</i> , 2017, 264, 1155-1164.	1.8	77
24	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	1.1	72
25	Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 977-987.e14.	1.5	66
26	Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 189-198.	1.5	61
27	The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1026-1036.	1.3	52
28	Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1000-1009.	0.6	51
29	Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study. <i>Journal of Dermatology</i> , 2019, 46, 680-685.	0.6	46
30	Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1523-1526.	1.5	45
31	Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. <i>Acta Dermato-Venereologica</i> , 2019, 99, 762-768.	0.6	45
32	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00402.	0.6	45
33	Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1943-1953.e13.	0.3	43
34	Nomenclature and clinical phenotypes of atopic dermatitis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110029.	1.1	43
35	Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. <i>British Journal of Dermatology</i> , 2022, 186, 453-465.	1.4	43
36	Dupilumab facial redness: Positive effect of itraconazole. <i>JAAD Case Reports</i> , 2019, 5, 888-891.	0.4	42

#	ARTICLE	IF	CITATIONS
37	Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 393-408.	3.3	36
38	Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1389-1392.e2.	2.0	33
39	Current and Future Biomarkers in Atopic Dermatitis. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 51-61.	0.7	32
40	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 101-115.	3.3	32
41	Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with <i>Demodex</i> and increased interleukin-17 levels?: reply from the authors. <i>British Journal of Dermatology</i> , 2018, 178, 1220-1221.	1.4	31
42	Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1160-1166.	0.6	28
43	Management of dupilumab-associated conjunctivitis in atopic dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 488-491.	0.4	27
44	Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2376-2379.	2.7	27
45	New Developments in Biomarkers for Atopic Dermatitis. <i>Journal of Clinical Medicine</i> , 2015, 4, 479-487.	1.0	26
46	EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1703-1705.	1.5	25
47	Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 159-170.	1.1	25
48	Specific IgE to fish extracts does not predict allergy to specific species within an adult fish allergic population. <i>Clinical and Translational Allergy</i> , 2014, 4, 27.	1.4	24
49	Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2019, 9, 799-805.	1.4	24
50	Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 125-134.	1.5	21
51	The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch <i>BioDay</i> Registry. <i>Contact Dermatitis</i> , 2022, 87, 185-191.	0.8	21
52	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1357-1372.	1.4	19
53	Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index. <i>Acta Dermato-Venereologica</i> , 2019, 99, 851-857.	0.6	17
54	EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3287-3289.	2.7	16

#	ARTICLE	IF	CITATIONS
55	Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. <i>Journal of Dermatological Treatment</i> , 2021, 32, 164-173.	1.1	15
56	Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 1-11.	3.3	15
57	Serum Creatinine Levels During and After Long-term Treatment with Cyclosporine A in Patients with Severe Atopic Dermatitis. <i>Acta Dermato-Venereologica</i> , 2015, 95, 963-967.	0.6	14
58	Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1608-1616.	1.1	14
59	Towards personalized treatment in atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 469-476.	1.4	12
60	Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3814-3817.	2.7	12
61	Ocular surface disease is common in moderate-to-severe atopic dermatitis patients. <i>Clinical and Experimental Allergy</i> , 2022, 52, 801-805.	1.4	12
62	Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study. <i>Dermatology and Therapy</i> , 2022, 12, 771-785.	1.4	11
63	Usage and Users of Online Self-Management Programs for Adult Patients With Atopic Dermatitis and Food Allergy: An Explorative Study. <i>JMIR Research Protocols</i> , 2015, 4, e57.	0.5	10
64	Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00585.	0.6	9
65	Sick Leave and Factors Influencing Sick Leave in Adult Patients with Atopic Dermatitis: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2015, 4, 535-547.	1.0	8
66	Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 341-349.	1.1	8
67	Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1257-1259.	0.6	7
68	Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1065.	1.5	7
69	EASI vs EASI : Predicting disease severity in atopic dermatitis patients treated with cyclosporin A. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 74, 613-617.	2.7	7
70	Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2240-2243.	2.7	7
71	Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. <i>Dermatitis</i> , 2021, 32, S81-S91.	0.8	7
72	Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00264.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. <i>Dermatology and Therapy</i> , 2022, 12, 223-231.	1.4	7
74	Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2022, 12, 1481-1491.	1.4	7
75	Management der Dupilumab-assoziierten Konjunktivitis beim atopischen Ekzem. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 488-492.	0.4	6
76	Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. <i>Dermatology and Therapy</i> , 2020, 10, 1415-1421.	1.4	6
77	Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. <i>BMJ Open</i> , 2020, 10, e033507.	0.8	6
78	Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1104-1108.	0.6	6
79	Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00666.	0.6	6
80	The Patient-Reported Disease Burden In Adults With Atopic Dermatitis: A Cross-Sectional Study In Canada and Europe. <i>Value in Health</i> , 2017, 20, A807.	0.1	5
81	Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1641-1644.	1.4	5
82	Modulation of Lymphocyte Function In Vivo via Inhibition of Calcineurin or Purine Synthesis in Patients with Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2476-2479.	0.3	4
83	Lymphopenia in atopic dermatitis patients treated with oral immunosuppressive drugs. <i>Journal of Dermatological Treatment</i> , 2018, 29, 682-687.	1.1	4
84	Time to get rid of the Investigator's Global Assessment as the primary outcome for clinical trials in atopic dermatitis?. <i>British Journal of Dermatology</i> , 2019, 181, 12-13.	1.4	4
85	Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1986-1989.	1.1	4
86	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 2147-2157.	1.4	4
87	First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding. <i>Journal of Dermatological Science</i> , 2016, 81, 66-68.	1.0	3
88	Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1499-1501.	0.6	3
89	Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). <i>Journal of Dermatological Treatment</i> , 2022, 33, 2565-2570.	1.1	3
90	Reply. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 753-754.	2.0	2

#	ARTICLE	IF	CITATIONS
91	Patterns of topical corticosteroids prescriptions in children with asthma. <i>Pediatric Dermatology</i> , 2018, 35, 378-383.	0.5	1
92	Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry. , 0, , .		1
93	Systemic treatment in atopic dermatitis after 2018: from experiencedâ€based treatment to evidenceâ€based treatment?. <i>British Journal of Dermatology</i> , 2020, 183, 987-988.	1.4	0
94	Efficacy of Dupilumab in Atopic Dermatitis: The Patientâ€™s Perspective. <i>Dermatology and Therapy</i> , 2021, 11, 2123-2131.	1.4	0
95	Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1ÂYear. <i>Dermatology and Therapy</i> , 2022, 12, 9-13.	1.4	0